-
11.发明申请公开(公告)号：US20200054678A1
公开(公告)日：2020-02-20
申请号：US16521430
申请日：2019-07-24
Applicant: Leiden University Medical Center
Inventor： Mirjam H.M. Heemskerk , J.H. Frederik Falkenburg
IPC: A61K35/17 , A61K39/00 , C07K14/725
Abstract: The technology relates in part to compositions and methods for inducing an immune response against the Preferentially Expressed Antigen of Melanoma (PRAME). Provided are methods for treating hyperproliferative diseases by inducing an immune response against PRAME antigen; the immune response may be induced by specifically targeting PRAME-expressing cells using T cell receptors directed against PRAME.
-
12.发明申请公开(公告)号：US20190300958A1
公开(公告)日：2019-10-03
申请号：US16258961
申请日：2019-01-28
Applicant: Celera Corporation , Leiden University Medical Center (LUMC) Acting on Behalf of Academic Hospital Leiden (AZL)
Inventor： Lance Bare , James J. Devlin , Frits R. Rosendaal , Pieter H. Reitsma , Irene D. Bezemer
IPC: C12Q1/6883 , A61K31/40 , A61K31/366 , A61K31/22 , A61K31/137 , A61K45/06 , A61K31/5377 , A61K45/00 , A61K31/4439 , A61K31/37 , A61K31/00 , A61K31/4545 , C07H21/04
Abstract: The present invention provides compositions and methods based on genetic polymorphisms that are associated with response to statin treatment (particularly for reducing the risk of venous thrombosis). For example, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by these nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and variant proteins, and methods of using the nucleic acid molecules and proteins as well as methods of using reagents for their detection.
-
公开(公告)号：US10189880B2
公开(公告)日：2019-01-29
申请号：US14930572
申请日：2015-11-02
Applicant: LEIDEN UNIVERSITY MEDICAL CENTER
Inventor： Mirjam H. M. Heemskerk , J. H. Frederik Falkenburg
IPC: C12N9/64 , C12N9/90 , A61K39/00 , C07K14/47 , C07K14/725 , C12N5/0783
Abstract: The technology relates in part to compositions and methods for inducing an immune response against a Bob1 antigen. Provided are methods for treating hyperproliferative diseases by inducing an immune response against a Bob1 antigen; the immune response may be induced using a Bob1 polypeptide fragment, or by specifically targeting Bob1-expressing cells using T cell receptors directed against Bob1.
-
公开(公告)号：US10058516B2
公开(公告)日：2018-08-28
申请号：US15546818
申请日：2016-01-28
Applicant: UNIVERSITY OF MARYLAND, BALTIMORE COUNTY , KATHOLIEKE UNIVERSITEIT LEUVEN , LEIDEN UNIVERSITY MEDICAL CENTER
Inventor： Katherine L. Radtke , Hannah L. Peters , Johan Neyts , Dirk Jochmans , Eric J. Snijder
IPC: C07D403/04 , A61K31/08 , A61K31/506 , A61K31/4178 , A61K45/06
CPC classification number: A61K31/08 , A61K31/4178 , A61K31/506 , A61K45/06 , A61K2300/00 , C07D403/04 , Y02P20/582
Abstract: The present invention is directed to compounds, methods and compositions for treating or preventing viral infections using nucleosides analogs. Specifically, the present invention provides for the design and synthesis of acyclic fleximer nucleoside analogues having increased flexibility and ability to alter their conformation structures to provide increased antiviral activity potential with the result of inhibiting several coronaviruses.
-
公开(公告)号：US20170007683A1
公开(公告)日：2017-01-12
申请号：US15115377
申请日：2015-01-30
Applicant: UNIVERSITÄT ZÜRICH , LEIDEN UNIVERSITY MEDICAL CENTER
Inventor： Anne Mueller , Daniela Engler-Anders , Christian Taube
IPC: A61K39/00 , A61K39/02 , A61K45/06 , C07K14/205
CPC classification number: A61K39/001 , A61K38/164 , A61K39/0208 , A61K45/06 , A61K2039/54 , A61K2039/542 , A61K2039/577 , C07K14/205
Abstract: The present invention is directed to polypeptides and compositions thereof useful for the prevention of treatment of allergic disorders, in particular atopic asthma. More particularly, the invention relates to tolerogenic agents and compositions thereof that are useful for the prevention and treatment of hypersensitivity to allergens, in particular and/or strategies of desensitization to allergens.
Abstract translation: 本发明涉及用于预防过敏性疾病，特别是特应性哮喘的治疗的多肽及其组合物。 更具体地说，本发明涉及可用于预防和治疗对变应原的过敏反应的特别是和/或对变应原脱敏的策略的致耐剂及其组合物。
-
Patent Agency Ranking
公开(公告)号：US20160129094A1
公开(公告)日：2016-05-12
申请号：US14930572
申请日：2015-11-02
Applicant: LEIDEN UNIVERSITY MEDICAL CENTER
Inventor： Mirjam H.M. HEEMSKERK , J.H. Frederik Falkenburg
IPC: A61K39/00 , C07K14/725 , C07K14/47 , C12N9/64
CPC classification number: C07K14/4702 , A61K39/00 , A61K39/0011 , C07K14/7051 , C07K2319/70 , C12N5/0636 , C12N9/6472 , C12N9/90 , C12N2510/00 , C12Y304/22062 , C12Y502/01008 , Y02A50/466
Abstract: The technology relates in part to compositions and methods for inducing an immune response against a Bob1 antigen. Provided are methods for treating hyperproliferative diseases by inducing an immune response against a Bob1 antigen; the immune response may be induced using a Bob1 polypeptide fragment, or by specifically targeting Bob1-expressing cells using T cell receptors directed against Bob1.
Abstract translation: 该技术部分涉及用于诱导针对Bob1抗原的免疫应答的组合物和方法。 提供了通过诱导针对Bob1抗原的免疫应答来治疗过度增殖性疾病的方法; 可以使用Bob1多肽片段诱导免疫应答，或者通过使用针对Bob1的T细胞受体来特异性靶向表达Bob1的细胞。
-
17.发明授权Inhibitors of the trypsin-like site of the proteasome and methods of use thereof 有权蛋白酶体的胰蛋白酶样位点的抑制剂及其使用方法公开(公告)号：US08609610B2
公开(公告)日：2013-12-17
申请号：US13723979
申请日：2012-12-21
Applicant: Trustees of Dartmouth College , Leiden University
Inventor： Alexei Kisselev , Dmitry V. Filippov , Herman Overkleeft
IPC: A61P33/00 , A61K38/00 , A61P35/00 , A61K38/55 , C07K14/81 , A61K38/04 , C07K5/00 , C07K7/00 , C07K16/00 , C07K17/00 , A61K38/06
CPC classification number: C07K5/1016 , A61K38/00 , A61K38/06 , A61K38/07 , A61K45/06 , C07K1/063 , C07K5/06043 , C07K5/06052 , C07K5/06078 , C07K5/06086 , C07K5/06095 , C07K5/0808 , C07K5/0812 , C07K5/0817
Abstract: The present invention is an inhibitor of the trypsin-like β2/β2i sites of the proteasome. The inhibitor is characterized as being a peptide-based epoxyketone or vinyl sulfone that contains an arginine or 4-aminomethylene-L-phenylalanine at the C-terminus (i.e., at the P1 position). Methods for using the inhibitor to inhibit the activity of the β2/β2i site of a proteasome and treat a proteasome-mediated disease or condition are also described.
Abstract translation: 本发明是蛋白酶体的胰蛋白酶样β2/β2i位点的抑制剂。 抑制剂的特征在于在C末端（即P1位置）含有精氨酸或4-氨基亚甲基-L-苯丙氨酸的肽类环氧酮或乙烯基砜。 还描述了使用抑制剂抑制蛋白酶体的β2/β2i位点的活性并治疗蛋白酶体介导的疾病或病症的方法。
-
18.发明申请公开(公告)号：US20130102527A1
公开(公告)日：2013-04-25
申请号：US13723979
申请日：2012-12-21
Applicant: Trustees Of Dartmouth College , Leiden University
Inventor： Alexei F. Kisselev , Dmitry V. Filippov , Herman Overkleeft
CPC classification number: C07K5/1016 , A61K38/00 , A61K38/06 , A61K38/07 , A61K45/06 , C07K1/063 , C07K5/06043 , C07K5/06052 , C07K5/06078 , C07K5/06086 , C07K5/06095 , C07K5/0808 , C07K5/0812 , C07K5/0817
Abstract: The present invention is an inhibitor of the trypsin-like β2/β2i sites of the proteasome. The inhibitor is characterized as being a peptide-based epoxyketone or vinyl sulfone that contains an arginine or 4-aminomethylene-L-phenylalanine at the C-terminus (i.e., at the P1 position). Methods for using the inhibitor to inhibit the activity of the β2/β2i site of a proteasome and treat a proteasome-mediated disease or condition are also described.
Abstract translation: 本发明是蛋白酶体的胰蛋白酶样β2/β2i位点的抑制剂。 抑制剂的特征在于在C末端（即P1位置）含有精氨酸或4-氨基亚甲基-L-苯丙氨酸的肽类环氧酮或乙烯基砜。 还描述了使用抑制剂抑制蛋白酶体的β2/β2i位点的活性并治疗蛋白酶体介导的疾病或病症的方法。
-
公开(公告)号：US20250101466A1
公开(公告)日：2025-03-27
申请号：US18715550
申请日：2022-12-02
Inventor： Zhihan ZHAO , Peng SHANG , Niels GEIJSEN
Abstract: The present disclosure provides efficient and precise methods and tools for use in the editing of nucleic acid. The disclosure provides a method of editing a nucleic acid comprising cutting or cleaving a nucleic acid to be edited, contacting the cut nucleic acid with a nucleic acid repair template so that the nucleic acid repair template comprises an end which matches a cut end of the nucleic acid to be edited and a sequence that is homologous to a sequence of nucleic acid to be edited.
-
公开(公告)号：US20220133766A1
公开(公告)日：2022-05-05
申请号：US17366662
申请日：2021-07-02
Inventor： Ronald Karel Louisa Van Brempt
IPC: A61K31/7088 , A61K38/17 , A61P9/00 , A61P11/00 , C12N15/113 , A61K45/06 , A61K45/00
Abstract: The disclosure is based on the finding that compounds capable of binding to (or interacting with) chromatin binding/remodelling complexes (for example Polycomb group PRC1 and Trithorax group MLL) and/or modulation of the same can be used to modulate (for example switch on/off) ciliogenesis as may occur, for example, in the human pulmonary bronchial epithelium. Provided are compounds, compositions, methods and medicaments which may be used to treat and/or prevent diseases and/or conditions associated with aberrant or defective ciliogenesis.
-
-
-
-
-
-
-
-
-
Search Results
53
records
(took 0.053 seconds)
